vs
Side-by-side financial comparison of Cheche Group Inc. (CCG) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $32.8M, roughly 1.8× Cheche Group Inc.).
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
CCG vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.8M | $57.6M |
| Net Profit | $153.6K | — |
| Gross Margin | 5.7% | 86.7% |
| Operating Margin | — | — |
| Net Margin | 0.5% | — |
| Revenue YoY | — | 94.1% |
| Net Profit YoY | — | 71.6% |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $32.8M | — | ||
| Q4 25 | — | $57.6M | ||
| Q3 25 | — | $49.5M | ||
| Q2 25 | $26.0M | $39.5M | ||
| Q1 25 | — | $28.5M | ||
| Q4 24 | $18.6M | $29.7M | ||
| Q3 24 | — | $16.4M | ||
| Q2 24 | $36.1M | $7.3M |
| Q1 26 | $153.6K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-30.0M | ||
| Q2 25 | $-492.4K | $-75.8M | ||
| Q1 25 | — | $-94.3M | ||
| Q4 24 | $-196.7K | — | ||
| Q3 24 | — | $-85.6M | ||
| Q2 24 | $-7.6M | $-91.4M |
| Q1 26 | 5.7% | — | ||
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | 4.9% | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | 5.2% | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | 4.3% | 81.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -30.8% | ||
| Q2 25 | -2.0% | -151.7% | ||
| Q1 25 | — | -276.5% | ||
| Q4 24 | -0.3% | — | ||
| Q3 24 | — | -433.0% | ||
| Q2 24 | -4.7% | -1055.4% |
| Q1 26 | 0.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -60.5% | ||
| Q2 25 | -1.9% | -191.9% | ||
| Q1 25 | — | -330.7% | ||
| Q4 24 | -1.1% | — | ||
| Q3 24 | — | -523.3% | ||
| Q2 24 | -21.0% | -1248.6% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.41 | ||
| Q2 25 | $-0.01 | $-1.05 | ||
| Q1 25 | — | $-1.31 | ||
| Q4 24 | $-0.00 | — | ||
| Q3 24 | — | $-1.32 | ||
| Q2 24 | — | $-1.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $130.0M |
| Total DebtLower is stronger | $193.3K | $209.1M |
| Stockholders' EquityBook value | — | $-438.2M |
| Total Assets | $203.5M | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.0M | — | ||
| Q4 25 | — | $130.0M | ||
| Q3 25 | — | $135.2M | ||
| Q2 25 | $23.1M | $149.6M | ||
| Q1 25 | — | $212.3M | ||
| Q4 24 | $21.1M | $297.3M | ||
| Q3 24 | — | $334.7M | ||
| Q2 24 | $28.2M | $276.2M |
| Q1 26 | $193.3K | — | ||
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | $690.0K | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-438.2M | ||
| Q3 25 | — | $-422.5M | ||
| Q2 25 | $47.1M | $-405.8M | ||
| Q1 25 | — | $-338.4M | ||
| Q4 24 | $49.1M | $-253.6M | ||
| Q3 24 | — | $-187.1M | ||
| Q2 24 | $48.6M | $-233.8M |
| Q1 26 | $203.5M | — | ||
| Q4 25 | — | $259.1M | ||
| Q3 25 | — | $240.3M | ||
| Q2 25 | $177.3M | $250.2M | ||
| Q1 25 | — | $294.2M | ||
| Q4 24 | $177.7M | $378.3M | ||
| Q3 24 | — | $387.0M | ||
| Q2 24 | $139.3M | $319.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-166.8M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | $-44.7M | $-62.7M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | $-15.8M | $-266.8M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | $-1.0K | $-70.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.8M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | $-16.0M | $-266.9M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | $-1.1K | $-70.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -159.0% | ||
| Q1 25 | — | -297.9% | ||
| Q4 24 | -85.9% | -899.8% | ||
| Q3 24 | — | -389.0% | ||
| Q2 24 | -0.0% | -966.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 1.2% | 0.5% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 0.0% | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
